Evaluation of Metabolic Markers for the Prediction of DDI of Various CYP3A Substrates and Inhibitors
Status:
Unknown status
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
Evaluation and validation of metabolic markers for the prediction of drug-drug interaction of
various CYP3A4 substrates (sildenafil) and inhibitors (erythromycin/itraconazole) in healthy
male subjects